title: Curcumin loaded microsponges for colon targeting in inflammatory bowel disease: fabrication, optimization, and in vitro and pharmacodynamic evaluation.
abstract: The present study was aimed to develop and optimize the microsponges of curcumin for colon specific drug delivery in a view to bypass the upper gastrointestinal tract (GIT) for enhanced therapeutic effect. Microsponges were developed by quasi emulsion solvent diffusion method using 3(2) full factorial design. Prepared microsponges were optimized in order to analyze the effects of independent variables (volume of ethanol and Eudragit L100) on the encapsulation efficiency, particle size, and drug release. The optimized formulation was subjected to in vivo study using acetic acid induced colitis model in rats. The F7 was selected as optimized formulation based on particle size of 41.63 μm, % entrapment efficiency of 78.13%, and % cumulative drug release of 84.12%, and desirability factor of 0.83. Release studies revealed that microsponges prevented the premature release of curcumin in upper GIT and specifically released the drug at colonic pH. The drug release profile of F7 formulation was subjected to different kinetic models and based upon the best correlation coefficient (r(2) = 0.9927) the release was found to follow Higuchi model, which suggested diffusion as the main mechanism of drug release. Pharmacodynamic study showed that curcumin loaded microsponges causes a significant decrease in edema, necrosis, and hemorrhage of colon as compared to free curcumin. This study proves that curcumin loaded microsponges may act as a promising drug delivery system for treatment of ulcerative colitis.
authors.affiliation: School of Pharmaceutical Sciences, Shoolini University, Bajhol, Solan, Himachal Pradesh 173229, India.
authors.forename: Rashmi
authors.identifier: 0000-0002-6279-8690
authors.initials: R
authors.lastname: Sareen
authors.affiliation: School of Pharmaceutical Sciences, Shoolini University, Bajhol, Solan, Himachal Pradesh 173229, India.
authors.forename: Kavita
authors.initials: K
authors.lastname: Nath
authors.affiliation: School of Pharmaceutical Sciences, Shoolini University, Bajhol, Solan, Himachal Pradesh 173229, India.
authors.forename: Nitin
authors.identifier: 0000-0002-2792-6044
authors.initials: N
authors.lastname: Jain
authors.affiliation: School of Pharmaceutical Sciences, Shoolini University, Bajhol, Solan, Himachal Pradesh 173229, India.
authors.forename: K L
authors.initials: KL
authors.lastname: Dhar
mesh_terms: D000818:Animals; D003106:Colon / Q000187:drug effects* / Q000473:pathology; D003474:Curcumin / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004333:Drug Administration Routes; D016503:Drug Delivery Systems; D004487:Edema / Q000188:drug therapy / Q000473:pathology; D006470:Hemorrhage / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D009336:Necrosis / Q000188:drug therapy / Q000473:pathology; D051381:Rats
chemical_list: D003474:Curcumin
references.citation: Int J Pharm. 2013 Jan 30;441(1-2):343-51
references.pmid: 23200955
references.citation: BMC Cancer. 2012 Nov 30;12:564
references.pmid: 23194063
references.citation: Pharm Dev Technol. 2013 Sep-Oct;18(5):1131-9
references.pmid: 23167303
references.citation: Colloids Surf B Biointerfaces. 2011 Apr 1;83(2):277-83
references.pmid: 21194900
references.citation: Curr Drug Deliv. 2013 Oct;10(5):564-71
references.pmid: 23360241
references.citation: Colloids Surf B Biointerfaces. 2011 Nov 1;88(1):231-9
references.pmid: 21778041
references.citation: Int J Pharm. 2012 May 10;427(2):153-62
references.pmid: 22306039
references.citation: Drug Dev Ind Pharm. 2007 Nov;33(11):1263-72
references.pmid: 18058323
references.citation: Asian Pac J Trop Biomed. 2012 May;2(5):337-44
references.pmid: 23569927
references.citation: Drug Dev Ind Pharm. 2000 May;26(5):549-54
references.pmid: 10789067
references.citation: Tohoku J Exp Med. 2005 Jun;206(2):131-9
references.pmid: 15888969
references.citation: Curr Drug Targets. 2013 Sep;14(10):1210-8
references.pmid: 23768171
references.citation: Eur J Pharm Sci. 2013 Jul 16;49(4):712-22
references.pmid: 23665411
references.citation: J Drug Deliv. 2012;2012:905191
references.pmid: 22577558
references.citation: Can J Surg. 2011 Oct;54(5):333-8
references.pmid: 21933527
references.citation: Int J Pharm. 2012 Jan 17;422(1-2):59-67
references.pmid: 22027394
references.citation: Curr Drug Deliv. 2011 Jul;8(4):407-15
references.pmid: 21453256
references.citation: AAPS PharmSciTech. 2009;10(2):402-9
references.pmid: 19381834
references.citation: Expert Opin Drug Deliv. 2012 Jul;9(7):863-78
references.pmid: 22663167
references.citation: World J Gastroenterol. 2011 Sep 28;17(36):4099-103
references.pmid: 22039323
references.citation: Int J Mol Sci. 2012;13(3):3959-3978
references.pmid: 22489192